Six months of CVT clinic attendance significantly improved A1C values and the overall percentage of patients meeting their goal A1C values in this veteran population. In addition, patient satisfaction scores also indicated a high level of satisfaction with the pharmacist-led CVT service.
Background:The purpose of this paper is to review the efficacy, safety, and tolerability of
linagliptin in the management of hyperglycemia in adults with type 2 diabetes
mellitus.Methods:A Medline search was performed using the keywords “linagliptin” and
“type 2 diabetes” for articles published September 2010 through July
2012. The literature search was limited by the following criteria: articles’
publication in the English language, clinical trials, randomized controlled trials, and
research conducted in humans.Results:A review of the data for linagliptin in the treatment of type 2 diabetes as monotherapy
or in combination with other antidiabetic therapies suggests clinical efficacy in terms
of reductions in glycosylated hemoglobin, fasting plasma glucose, and postprandial
glucose. Most adverse events with linagliptin are considered to be mild to moderate in
nature. Although linagliptin therapy may offer a low risk of hypoglycemia, the risk
increases when it is used in combination with insulin secretagogues. Linagliptin can
generally be considered weight neutral, but a weight increase was observed when
linagliptin was used in combination with a thiazolidinedione.Conclusion:Linagliptin is a once-daily oral medication used for the treatment of type 2 diabetes.
The use of linagliptin as monotherapy or in combination with metformin, sulfonylureas,
or pioglitazone led to improvement in glycemic control and was well tolerated by most
patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.